Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Sarcoma 2Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Hodgkin Disease 1Hematologic Neoplasms 1Hemangiosarcoma 1Dermatofibrosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Carboplatin 25Etoposide 23Cisplatin 16pembrolizumab 9Topotecan 9atezolizumab 7Pemetrexed 7Nivolumab 7Radiosurgery 6Irinotecan 5durvalumab 4Paclitaxel 4Gemcitabine 4Albumin-Bound Paclitaxel 4rovalpituzumab tesirine 3etoposide phosphate 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Cyclophosphamide 3vistusertib 2roniciclib 2pelcitoclax 2pazopanib 2epacadostat 2amrubicin 2Vorinostat 2Radiation 2Fluorodeoxyglucose F18 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Small Cell Lung Carcinoma × TTI-621 × Clear all
NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡